Overactive Bladder: Global Drug Forecast and Market Analysis to 2030
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The overactive bladder (OAB) market sales have been valued at $2.2 billion in 2020 across the eight major markets (8MM) covered in this report- the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan and China. The market is projected to grow at a CAGR of more than 2% during the period 2021-2030. The US accounted for the largest market with global sales in 2020, equating to a market share of more than 45%. This largely reflects the large prevalence population in the US and the high cost of drug therapy in this market. Myrbetriq is currently the leading OAB therapy with global sales in 2020, equating to a market share of more than 50%.
The considerable growth expected during the mid-to-late forecast period reflects a continued trend for increased OAB prevalence, as well as the anticipated launch of several pipeline agents. As previously discussed, the late-stage pipeline is scarce with no products in Phase III development or the Pre-registration stage of development although there are a limited number of products in Phase II development.
Overview of the overactive bladder market
For more insights on this report, download a free report sample
What are the market dynamics in the OAB drug market?
The major drivers of market growth over the forecast period are the continued uptake of the beta-3 agonist Gemtesa (marketed as Beova in Japan) in Japan and the US and the potential launch of this product in China, The potential launch of pipeline agents in the mid-to-late forecast period. These include Bayer’s P2X purinoceptor 3 (P2RX3) antagonist Eliapixant in the global market, Urovant Sciences’ gene therapy URO-902 in the US market, and Taiho Pharmaceuticals’ neurite outgrowth enhancer TAC 302 in the Japanese market. All these products employ novel mechanisms of action and are currently in Phase II development and increase in the prevalence of OAB over the forecast period owing to trends such as aging populations and rising obesity, leading to an increase in the population of diagnosed prevalent cases.
Generic sales erosion of VESIcare, Myrbetriq, and Toviaz due to recent and upcoming patent expirations in key markets, including the US. The scarcity of the late-stage pipeline. In particular, the lack of drugs in Phase III development or the pre-registration stages of development will restrict market growth over the early-to-mid forecast period. Moreover, factors that contribute to low rates of diagnosis and treatment are expected to persist over the forecast period. These include stigma and misinformation surrounding OAB, which deters patients from seeking medical help, as well as poor persistence and adherence to drug therapy. The major barriers to market growth over the forecast period are the factors which contribute to low rates of diagnosis and treatment are expected to persist over the forecast period. These include stigma and misinformation surrounding OAB, which deters patients from seeking medical help, as well as poor persistence and adherence to drug therapy.
What are the diagnosed incident cases of OAB in the 8MM?
In 2020, China accounted for more than 60% of the total prevalent cases of OAB in the 8MM, with 222,928,413 cases, while the US accounted for more than 15% of the total prevalent cases of overactive bladder with 68,942,473 cases. There were more than 15% of the total prevalent cases in the 5EU, while Japan had more than 4% of cases. In the 8MM, the total prevalent cases of OAB will grow by more than 10% over the forecast period at an Annual Growth Rate (AGR) of more than 1%, from 363,318,429 cases in 2020. Of the 8MM, China is expected to have the highest AGR of more than 1%. Spain had the lowest number of total prevalent cases of OAB in 2020. Any change in the total prevalent cases of OAB is attributable to changing population demographics in the 8MM.
Diagnosed incident cases of OAB in the 8MM, by country
For more regional insights, download a free report sample
Which are the major players in the OAB drug market?
The major players in the market are Allergan, Astellas, Pfizer, Urovant Sciences, Bayer, Taiho Pharmaceuticals and Kyorin Pharmaceutical.
OAB drug market, by key players
For more insights on key players, download a free report sample
Market report scope
Market size (Year – 2020) | $2.2 billion |
Growth rate (CAGR) | >2% |
Base year | 2020 |
Forecast Period | 2021-2030 |
Key Countries | The US, 5EU (France, Germany, Italy, Spain, and the UK) |
Key Players | Allergan, Astellas, Pfizer, Urovant Sciences, Bayer, Taiho Pharmaceuticals and Kyorin Pharmaceuticals |
Scope
This report provides an in-depth analysis of the following:
- Overview of OAB, including classification, epidemiology, etiology, pathophysiology, diagnosis, and disease management.
- Topline OAB therapeutics market revenue for 2020-2030 (includes the annual cost of therapy and anticipated sales for major late-stage pipeline drugs).
- Key topics covered include current treatment options, clinical trials landscape, unmet needs and opportunities, R&D strategies, drivers and barriers of market growth, current and future players, and market outlook.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global OAB drug market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most promising pipeline assets.
- Develop business strategies by understanding the trends shaping and driving the global OAB drug market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global OAB drug market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Astellas
Bayer
DelNova
Dompe Farmaceutici
Dong-A ST Co.
Ion Channel Innovations
Johnson & Johnson
Kissei Pharmaceutical
Korea United Pharm
Kyorin Pharmaceutical
Merck & Co
Mezzion Pharma
Pfizer
Roivant Sciences
Sinovant Sciences
Sinsin Pharmaceutical
Taiho Pharmaceuticals
TARIS Biomedical
Urovant Sciences
Viatris
XuanZhu Biological Technology Co.
Table of Contents
Table
Figures
Frequently asked questions
-
What was the market size of the overactive bladder (OAB) drug market in 2020?
The overactive bladder (OAB) market was valued at $2.2 billion in 2020.
-
What is the growth rate of the overactive bladder (OAB) drug market?
The overactive bladder (OAB) market is projected to grow at a CAGR of more than 2% during 2021-2030.
-
Which country has the highest number of diagnosed incident cases of OAB?
In 2020, China accounted for more than 60% of the total prevalent cases of OAB in the 8MM.
-
Who are the major players in the OAB drug market?
The major players in the market are Allergan, Astellas, Pfizer, Urovant Sciences, Bayer, Taiho Pharmaceuticals and Kyorin Pharmaceuticals.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.